Symphogen A/S Enters into Strategic Collaboration with Genentech, Inc. for Antibody Therapeutics in Infectious Disease

June 10, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen A/S announced today that it has entered into a global strategic collaboration with Genentech, Inc. for antibody therapeutics against three undisclosed infectious disease targets.

Twitter
LinkedIn
Facebook
Email
Print

Alliances Europe

Genentech, Inc.